177Lu-PSMA-617
novartis
['crpc']
[177lu]lu-psma-617 in psma-positive #mcrpc: prior and concomitant treatment subgroup analyses of the #vision trial. presented by nitin vaishampayan . #asco22 written coverage by &gt; 
Largest global online community of #urological medical professionals & patients. #AUA22 #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology